Ultragenyx Opens Gene Therapy Manufacturing Facility in Massachusetts

Rare Daily Staff

Ultragenyx Pharmaceutical said it opened its new 110,000-square-foot gene therapy manufacturing facility in Bedford, Massachusetts near its Greater Boston area R&D operations.

The company plans to hire 120 employees to staff the facility from a range of skill levels and backgrounds. Ultragenyx currently employs more than 350 people in Massachusetts across its sites in Bedford, Woburn, and Cambridge.

“Today we’re celebrating the result of several years’ worth of effort by hundreds of people, all driven by a single shared goal – to transform the lives of people living with rare disease,” said Dennis Huang, chief technical operations officer and executive vice president for gene therapy research and development at Ultragenyx. “Through this facility, Ultragenyx will develop and produce gene therapy treatments at greater scale than previously possible, which we believe will make these rare disease medicines more accessible to the people who need them.”